Stocktoria
Ovid Therapeutics Inc. OVID
Ovid Therapeutics Inc. (OVID) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $7.3M at a -240.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.438 |
| Retained earnings / assets | -2.131 |
| EBIT / assets | -0.281 |
| Equity / liabilities | 6.445 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| IMNM | Immunome Inc. | 3/9 | 13.87 | — | — |
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2/9 | 6.19 | — | — |
| ACRS | Aclaris Therapeutics, Inc. | 2/9 | -18.21 | — | -58.2% |
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
FAQ
Is OVID financially healthy?
Ovid Therapeutics Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does OVID pay a dividend?
No, Ovid Therapeutics Inc. does not currently pay a dividend.
How profitable is OVID?
In FY2025, Ovid Therapeutics Inc. had a net margin of -240.1% and a return on equity of -13.3%.
What is the analyst price target for OVID?
The average Wall-Street price target for Ovid Therapeutics Inc. is $5.47, about 108.8% above the recent price, from 9 analysts.
Is OVID a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Ovid Therapeutics Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.